Technical Analysis for RDY - Dr. Reddy's Laboratories Ltd

Grade Last Price % Change Price Change
D 14.09 -1.47% -0.21
RDY closed down 0.35 percent on Wednesday, November 20, 2024, on 1.36 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction -1.47%
Oversold Stochastic Weakness -1.47%
Slingshot Bearish Bearish Swing Setup -1.81%
Lower Bollinger Band Walk Weakness -1.81%
Oversold Stochastic Weakness -1.81%
Doji - Bullish? Reversal -0.07%
Lower Bollinger Band Walk Weakness -0.07%
Down 3 Days in a Row Weakness -0.07%
Down 4 Days in a Row Weakness -0.07%
Down 5 Days in a Row Weakness -0.07%

   Recent Intraday Alerts

Alert Time
Down 2 % 28 minutes ago
Down 1 ATR 28 minutes ago
Gapped Down (Full) 40 minutes ago
Fell Below Previous Day's Low 40 minutes ago
Down 1% 40 minutes ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dr. Reddy's Laboratories Ltd Description

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in the operation of biologics business. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. It offers new, synergistic combination, and technology formulations that modifies pharmacokinetics of existing medicines. This segment is also involved in the Company's specialty pharmaceuticals business that includes sales and marketing operations for in-licensed and co-developed dermatology. The company offers its products and services primarily in the areas of gastrointestinal, cardiovascular, pain management, and oncology therapies. It primarily operates in India, the United States, Russia and other countries of the former Soviet Union, Europe, and others. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Products Gastrointestinal Pain Management Dermatology Active Pharmaceutical Ingredients Pharmacokinetics Chemical Entities Oncology Therapies Contract Research Services Pharmaceutical Industry In India Pharmaceutical Services Biotech And Pharmaceutical

Is RDY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.892
52 Week Low 12.7474
Average Volume 779,437
200-Day Moving Average 15.09
50-Day Moving Average 15.42
20-Day Moving Average 14.81
10-Day Moving Average 14.57
Average True Range 0.29
RSI (14) 35.06
ADX 37.99
+DI 13.54
-DI 33.50
Chandelier Exit (Long, 3 ATRs) 15.07
Chandelier Exit (Short, 3 ATRs) 14.83
Upper Bollinger Bands 15.67
Lower Bollinger Band 13.95
Percent B (%b) 0.2
BandWidth 11.60
MACD Line -0.35
MACD Signal Line -0.31
MACD Histogram -0.0462
Fundamentals Value
Market Cap 2.38 Billion
Num Shares 167 Million
EPS 3.77
Price-to-Earnings (P/E) Ratio 3.79
Price-to-Sales 0.05
Price-to-Book 3.82
PEG Ratio 4.87
Dividend 40.00
Dividend Yield 279.72%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.54
Resistance 3 (R3) 14.55 14.47 14.50
Resistance 2 (R2) 14.47 14.41 14.47 14.49
Resistance 1 (R1) 14.39 14.37 14.35 14.38 14.47
Pivot Point 14.31 14.31 14.30 14.31 14.31
Support 1 (S1) 14.23 14.25 14.19 14.22 14.13
Support 2 (S2) 14.15 14.21 14.15 14.11
Support 3 (S3) 14.07 14.15 14.10
Support 4 (S4) 14.06